Q1 2023

Filed May 15, 2023 · 10-Q · 45 days after period end · 0001477932-23-003594

Q1 2023 · 10-Q

Revenue

$40.44K

+97.1% vs Q1 2022

Net Income

-$1.01M

N/M vs Q1 2022

EPS, diluted—

Operating Income-$1,056,315N/M

Operating Cash Flow-$397,355N/M

Same quarter

Metric	Q1 2023	Q1 2022	Q1 2021	Q1 2020
Revenue	$40.44K	$20.52K	$10.12K	$36.90K
Net Income	-$1.01M	-$944.99K	-$1.58M	-$1.08M
EPS Diluted	—	—	-$0.26	-$0.20

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR